miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer remains a leading cause of cancer death in women globally.
• Tumor invasiveness and drug resistance complicate treatment effectiveness.
• SDCBP is overexpressed in breast cancer, correlating with poor prognosis, but its regulation is unclear.

Purpose of the Study:

• To investigate the post-transcriptional regulation of SDCBP in breast cancer.
• To elucidate the role of miR-216b in breast cancer progression and its relationship with SDCBP.
• To explore the therapeutic potential of targeting the miR-216b/SDCBP axis.

Main Methods:

• Investigated miR-216b's direct regulation of SDCBP via 3'UTR binding.
• Assessed the impact of miR-216b overexpression and inhibition on breast cancer cell proliferation, migration, and invasion in vitro.
• Analyzed the correlation between miR-216b and SDCBP expression in breast cancer tissues and cell lines.
• Evaluated the effect of simultaneous miR-216b and SDCBP expression on cancer cell behavior.

Main Results:

• miR-216b directly binds to the 3'UTR of SDCBP, regulating its expression.
• miR-216b is underexpressed in metastatic breast cancer and acts as a tumor suppressor.
• Overexpression of miR-216b decreased breast cancer cell proliferation, migration, and invasion by modulating SDCBP.
• Inhibition of miR-216b promoted cancer cell growth, migration, and invasion.
• A negative correlation exists between miR-216b and SDCBP expression in breast cancer.
• Simultaneous expression of miR-216b and SDCBP reversed the observed effects, indicating SDCBP mediates miR-216b's tumor-suppressive actions.

Conclusions:

• Identified miR-216b as a key regulator of SDCBP expression in breast cancer.
• The miR-216b/SDCBP axis represents a potential therapeutic target for breast cancer.
• Restoring miR-216b function could offer a novel treatment strategy for this disease.